Hidden, Absorbed, and Unaccounted Costs in Clinical Trials

Clinical trials are widely recognized as expensive and complex projects. Budget discussions usually focus on visible cost elements such as labour fees, investigator grants, site payments, vendor contracts, other passthorough. These costs are clearly documented in study budgets and contracts and are typically tracked through project accounting systems.

However, the real operational cost of clinical trials often extends beyond these visible budget lines. During study execution, additional effort frequently arises from inefficient processes, fragmented systems, and operational challenges that require extra coordination by project teams.

Some of this work eventually appears in project effort reports. Some of it is absorbed by organizations when project budgets are exceeded. And some effort may never be formally recorded at all.

To illustrate this situation, it can be useful to distinguish between four different categories of costs in clinical trial operations: visible costs, hidden costs, absorbed costs, and unaccounted costs.

Visible Costs in Clinical Trials

Visible costs are the most familiar component of clinical trial budgets. These costs are planned during study design and typically appear both in project budgets and in financial reporting.

Examples include:

• investigator grants and site payments

• vendor contracts and laboratory services

• clinical monitoring activities

• data management and statistical services

• regulatory and project management activities

These activities are usually supported by project budgets and tracked through time sheets or contractual agreements. As a result, the effort and financial impact of these activities are visible to both project management and financial reporting systems.

Hidden Costs: Operational Inefficiencies

Hidden costs arise from inefficiencies embedded in clinical trial processes. These costs are rarely planned explicitly but emerge during the day-to-day execution of the study.

Examples may include:

• reconciliation between multiple clinical systems

• repeated document corrections or quality checks

• redundant data entry across platforms

• administrative work required to resolve inconsistencies

In most organizations, the time required to perform these tasks is recorded in time sheets. However, these costs may not be immediately visible during budgeting because they result from operational complexity rather than explicitly planned activities.

For this reason, hidden costs often appear only indirectly, through increased operational effort over the course of the study.

Absorbed Costs: When the Organization Carries the Burden

Another category of cost emerges when project teams perform additional work that exceeds the original project budget but cannot be billed to the sponsor.

Examples may include:

• additional project coordination required to resolve operational issues

• increased monitoring or documentation work not covered by the contract

• operational effort exceeding the original budget assumptions

In many organizations, employees still record these hours in time sheets. However, because the sponsor contract does not allow additional billing, the organization must absorb the cost internally.

These absorbed costs may therefore reduce project margins or require internal budget adjustments, even though the effort itself is fully recorded.

Unaccounted Costs: Work That Never Enters the System

A third category involves work that never enters project accounting or time-tracking systems.

Examples may include:

• responding to operational issues outside regular working hours

• resolving small discrepancies informally

• short administrative tasks not logged in time tracking systems

In these situations, the work may be visible to the individuals performing it but remains unaccounted for in formal reporting systems.

Because these efforts are not recorded in time sheets, they also do not appear in study budgets or financial reports.

An Illustrational View of Cost Visibility

The following table illustrates how these different types of costs may appear across time tracking and financial reporting systems.

Cost Type	Recorded in Time Sheets	Reflected in Study Budget or Financial Reporting
Visible costs	Yes	Yes
Hidden costs	Yes	Sometimes (through increased effort)
Absorbed costs	Yes	No (absorbed internally by the organization)
Unaccounted costs	No	No

These categories describe how operational effort may appear differently in time tracking, project budgets, and financial reporting. The distinctions are illustrational and may vary across organizations.

Why This Distinction Matters

Understanding these categories can help explain why clinical trials often require more effort than originally expected.

Hidden costs reflect inefficiencies in operational processes.
Absorbed costs reflect situations where organizations internally carry additional effort.
Unaccounted costs highlight limitations in how work is recorded and reported.

Together, these factors contribute to the overall operational burden of clinical trials, even when formal study budgets appear well defined.

Recognizing these different layers of cost can therefore help organizations better understand how clinical trial work is actually performed and where opportunities for improvement may exist.

Looking Forward

Improving clinical trial efficiency is often discussed in the context of digital transformation and new technology. However, reducing operational complexity requires not only better systems but also clearer visibility into how work is performed.

Distinguishing between visible, hidden, absorbed, and unaccounted costs provides one possible way to better understand the true operational effort behind clinical research.

While this framework is only illustrative, it may help highlight areas where process design, system integration, and operational planning could reduce unnecessary workload and improve efficiency in clinical trials.

In the end, the true cost of a clinical trial is not only what appears in the study budget, but also the operational effort required to make the study work in practice.

References

Gumber L, Agbeleye O, Inskip A, et al

Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions

BMJ Open 2024;14:e077132. doi: 10.1136/bmjopen-2023-077132

Achieving best-in-class clinical trial delivery: The road to 2035

https://www.mckinsey.com/industries/life-sciences/our-insights/achieving-best-in-class-clinical-trial-delivery-the-road-to-2035

What Are AI Agents and How Can They Help Optimize Clinical Trial Operations

Removing duplication in clinical trial operations could significantly reduce costs and increase research capacity. One emerging technology that may help enable this transformation is the concept of AI agents. But what exactly are AI agents, and how could they improve clinical trial operations?

What are AI agents?

An AI agent is a software system designed to perform tasks autonomously based on defined goals, available data, and operational rules.

Traditional software typically executes predefined commands. AI agents, in contrast, can interpret information, analyze context, and trigger actions within complex workflows.

In practical terms, AI agents can:

• interpret structured information

• coordinate operational processes

• trigger workflows across systems

• monitor data and identify anomalies

• generate reports or documentation

Rather than acting only as databases or static tools, AI agents can function as digital operators that help coordinate processes and information flows.

Why clinical trial operations are suitable for AI agents

Clinical trials involve large numbers of structured tasks and repetitive operational activities.

Examples include:

• configuring trial systems

• coordinating study startup activities

• monitoring trial progress

• managing documentation and regulatory records

• reconciling data across systems

• coordinating vendors and research sites

Many of these activities follow predictable workflows defined by protocols, regulatory requirements, and operational plans.

This makes clinical trial operations particularly suitable for agent-based automation.

Instead of teams manually coordinating information across multiple systems and spreadsheets, AI agents could help orchestrate workflows across the trial lifecycle.

Where AI agents could support clinical trial operations

AI agents could assist with several operational areas in clinical research.

1. Protocol interpretation

Clinical protocols describe visits, procedures, and data collection requirements.

AI agents could help interpret structured protocol information and generate operational elements such as:

• study timelines

• visit schedules

• monitoring plans

• data collection structures

This could help accelerate trial setup and reduce manual configuration work.

2. Trial budgeting and feasibility

Clinical trial budgets depend on many variables, including:

• number of sites

• visit schedules

• procedures per visit

• monitoring strategies

• regional cost differences

AI agents could support scenario modeling, helping sponsors estimate operational effort and evaluate alternative study designs.

This could enable more data-driven decisions during trial planning.

3. Workflow coordination

Clinical trial operations require coordination across many stakeholders and systems.

Examples include:

• site activation

• monitoring schedules

• regulatory documentation

• vendor coordination

AI agents could track operational events and automatically trigger the next required step in the workflow.

For example:

Site activation → monitoring schedule generated → documentation prepared → operational milestone recorded.

4. Monitoring and data quality

Monitoring is one of the largest operational components of clinical trials.

AI agents could assist with:

• centralized monitoring

• anomaly detection in trial data

• automated monitoring summaries

• identification of potential risks

Instead of manually reviewing large volumes of data, monitors could focus on targeted investigations triggered by intelligent alerts.

5. Documentation and compliance

Clinical trials require extensive documentation for regulatory compliance.

AI agents could help generate or update documents based on operational events, including:

• monitoring reports

• operational summaries

• trial progress reports

• audit preparation materials

This could reduce repetitive documentation work and minimize duplicate data entry.

Connecting AI agents with operational simplification

AI agents do not replace scientific expertise, investigators, or clinical judgment.

Their role is to coordinate operational complexity.

When systems, workflows, and operational events are structured properly, AI agents could help:

• reduce manual reconciliation between systems

• eliminate duplicate data entry

• automate repetitive operational tasks

• improve visibility across trial operations

In this way, AI agents could become an important component of more integrated and efficient clinical trial operations.

Conclusion

AI agents have the potential to automate many operational tasks in clinical trial management, reducing repetitive manual work and helping teams coordinate increasingly complex research processes. By supporting activities such as workflow orchestration, data monitoring, and documentation, agent-based systems could improve operational efficiency across the clinical trial lifecycle.

At the same time, automation does not eliminate risk—it changes its nature. Some traditional human errors may decrease, but new risks can emerge, including incorrect AI-generated outputs or so-called hallucinations. For this reason, AI-assisted workflows will likely continue to rely on human oversight and validation, particularly in regulated environments such as clinical research. As AI technologies mature, improved models, validation frameworks, and regulatory guidance may further reduce these risks while allowing researchers to benefit from more intelligent and efficient operational systems.

Ultimately, the goal is not simply automation, but better coordination of clinical research operations, enabling teams to focus more on scientific discovery and patient outcomes.

References:

1. AI Agents in Clinical Trial Operations

Ménard, T., & Bramstedt, K. (2025).
Artificial Intelligence Agent in Clinical Trial Operations – A Case Study.

This paper discusses how AI agents could manage tasks such as monitoring electronic case report forms, detecting anomalies, and generating reports that currently require large amounts of human effort.

https://www.researchgate.net/publication/389687417_Artificial_Intelligence_Agent_in_Clinical_Trial_Operations_-_a_Fictional_for_now_Case_Study

2. AI Agents in Healthcare Systems

Zhao, L. et al. (2026).
AI Agent in Healthcare: Applications, Evaluation, and Future Directions.

This review describes how AI agents can autonomously orchestrate complex workflows, analyze multimodal clinical data, and support operational tasks across healthcare systems.

https://www.nature.com/articles/s44387-026-00076-4

3. Autonomous Agents in Clinical Research Operations

Applied Clinical Trials (2025).
Setting the Limits of Autonomy with AI Agents in Clinical Research.

This article discusses how agent-based automation could reduce timelines by handling repetitive administrative tasks, data management activities, and document workflows while keeping humans in the loop for regulatory oversight.

https://www.appliedclinicaltrialsonline.com/view/setting-limits-autonomy-autonomous-agents-clinical-research

Could Clinical Trial Costs Be Reduced by Half?

Could Halving Clinical Trial Costs Double the Benefits of Clinical Research?

Clinical trials are essential for developing new therapies, but they are also widely known to be expensive. Conducting a single clinical study often requires large budgets, complex coordination, and significant operational infrastructure.

But this raises an important question: How much of the cost of clinical trials is driven by scientific requirements—and how much is driven by operational complexity?

Clinical trials must support patient care, medical procedures, and the evaluation of investigational treatments. These elements are essential and cannot be eliminated. However, a substantial portion of clinical trial budgets is also devoted to coordinating processes, documenting activities, reconciling information across systems, and managing regulatory workflows.

In this sense, clinical trials are not only scientific investigations. They are also large operational systems.

Understanding how these systems are organized may reveal opportunities to improve efficiency without compromising scientific quality.

Some observations about operational inefficiency

Several structural patterns appear frequently in modern clinical trial operations.

• If information must be entered into multiple systems, the cost of producing that information multiplies. Clinical trials commonly rely on multiple platforms such as CTMS, EDC, IRT, and eTMF, each responsible for different operational functions.

• When systems do not integrate naturally, organizations spend resources reconciling information between them. A large share of operational work becomes the process of verifying that different systems agree with each other.

• Many operational costs arise not from generating data, but from aligning fragmented workflows.

• Monitoring and verification activities represent a substantial share of trial costs. Source Data Verification alone has been estimated to account for 25–40% of monitoring effort in some studies.

• Operational complexity often grows faster than scientific complexity. Over time, additional systems and processes are introduced to meet new requirements, while the overall workflow remains largely unchanged.

• Every additional system introduces coordination and reconciliation costs. Separate platforms, spreadsheets, and communication channels create layers of operational overhead.

Taken together, these patterns suggest that a significant share of clinical trial effort is devoted not to scientific discovery, but to managing fragmented operational processes.

If duplication and reconciliation could be reduced, the overall operational burden might decrease significantly.

Understanding the structure of clinical trial budgets

Clinical trial budgets typically consist of three main components.

Sponsor or CRO operational fees: These include the activities required to manage and coordinate the study:project management, monitoring, data management, regulatory coordination, statistical analysis

Operational management often represents a significant share of total trial cost, especially in multi-site studies.

Pass-through costs: Pass-through costs are external expenses that sponsors pay for services required by the study.

Examples include:

• laboratory tests

• imaging procedures such as MRI or CT

• central laboratory services

• drug logistics and supply

• patient recruitment services

These costs depend largely on protocol design and trial complexity.

Investigator grants: Investigator grants are payments to clinical research sites conducting the trial.

They typically cover:

• investigator and study coordinator time

• patient visit management

• regulatory documentation

• site infrastructure and overhead

These costs vary widely depending on therapeutic area, geography, and study design.

Can all costs be optimized?

Not all clinical trial costs can be reduced.

Medical procedures, investigational products, and patient care are essential elements of clinical research.

However, the operational architecture of clinical trials strongly influences how efficiently these activities are coordinated.

Well-designed studies can optimize:

• monitoring strategies

• protocol complexity

• site workflows

• system integration

• documentation processes

When trial operations are carefully structured, improvements may influence all three cost categories—fees, pass-through costs, and investigator grants.

Why the idea of “half the cost” appears

The idea that clinical trial costs could potentially be reduced by half should not be interpreted as a precise prediction.

Instead, it reflects a structural observation:

When operational systems contain duplication and parallel workflows, removing redundant steps can dramatically reduce total effort.

If operational processes require the same information to be entered, verified, and documented multiple times, organizations effectively pay for the same work repeatedly.

Reducing duplication does not simply reduce software costs. It also reduces the labor required to manage parallel workflows.

In many industries, eliminating redundant operational processes has produced efficiency improvements of one-third to one-half of total effort.

Clinical trials may contain similar opportunities, particularly in areas such as:

• manual documentation

• system reconciliation

• monitoring administration

• operational coordination

Why this question matters?

If clinical trial costs could be significantly reduced, even by one-third or one-half in some cases, the implications would extend far beyond operational efficiency.

Lower costs could allow research organizations to conduct more studies and explore more scientific hypotheses, increasing the likelihood of important discoveries.

Operational improvements could also reduce the administrative burden placed on clinical research professionals. By decreasing repetitive manual tasks and system reconciliation work, teams could focus more on scientific thinking, patient care, and study design.

This shift may also help address a persistent challenge in clinical research: workforce fatigue and administrative overload.

More efficient operational systems could therefore support:

• more clinical studies conducted with the same resources

• faster testing of new therapeutic hypotheses

• reduced administrative burden on research staff

• greater focus on scientific and clinical decision-making

• broader participation of smaller institutions and academic groups in research

Ultimately, improving the operational architecture of clinical trials is not only about reducing cost.

It is about freeing scientific capacity.

If clinical trial costs could be substantially reduced, the same research budgets might support twice the research activity, leading to more discoveries, more treatments, and healthier patients.

Validation vs Usability in Clinical Trial Systems: Balancing Reactive Control and Preventive Design

Clinical research operates within a tightly regulated environment in which digital systems are subject to rigorous validation requirements. Data capture platforms, trial master file systems, safety databases, and financial tracking tools must demonstrate reliability, traceability, and compliance with Good Clinical Practice principles. Validation is foundational. Without it, data integrity and participant safety cannot be assured.

Yet validation alone does not guarantee that a system supports efficient and stable trial execution. A platform may perform exactly as specified under documented test conditions, and still generate friction in day-to-day operations. This distinction between validation and usability is rarely explored explicitly, but it carries structural implications for quality management in clinical research.

Under frameworks such as ICH E6(R2) and ICH E6(R3), computerized systems must be fit for purpose and maintain data integrity throughout the study lifecycle. The regulatory emphasis is appropriately placed on reliability, auditability, and control. However, “fit for purpose” can be interpreted narrowly as technical compliance, or more broadly as operational adequacy. The difference matters.

Validation confirms that a system behaves as intended according to predefined requirements. It answers the question: does the software function correctly under documented scenarios? 

Usability, by contrast, addresses whether real users can execute complex workflows efficiently, consistently, and without excessive workaround behavior. It asks: does the system support how work is actually performed in a clinical trial?

Is Clinical Trial Software Truly Fit for Purpose?

Clinical research today operates within a dense digital ecosystem. Electronic data capture systems, trial master file platforms, safety databases, project portfolio tools, and financial tracking solutions collectively form the infrastructure of modern study execution. From a technical standpoint, these systems are validated, cloud-enabled, and increasingly interoperable. Yet a more fundamental question often remains insufficiently examined: does the existing software landscape actually cover the functionality required by the study it supports?

The concept of “fit for purpose” is frequently used in regulated environments, particularly under frameworks such as ICH E6(R2) and ICH E6(R3). Within this context, systems must ensure data integrity, reliability, traceability, and appropriate documentation. However, regulatory compliance alone does not automatically imply operational adequacy. A system may meet validation standards and still fall short in representing the real operational complexity of a study.

Clinical Trial Automation: The Naming Conventions Challenge

Is cross-system clinical trial automation failing not because workflows cannot be executed, but because protocol terminology cannot be interpreted consistently across systems and clinical studies?

Discussions about automating clinical trials often focus on advanced technologies such as workflow engines, interoperability standards, and AI/ML. In practice, cross-system automation most often breaks much earlier, at a far more basic level: inconsistent naming conventions. 

Clinical protocols are written in natural language, where the same term can legitimately carry different meanings depending on study design, therapeutic area, or regulatory intent. Software systems, by contrast, assume that identifiers are stable, explicit, and unambiguous. This mismatch creates friction long before questions of execution logic or governance arise.

Several academic and industry initiatives have proposed encoding protocol elements, such as eligibility criteria, visits, milestones, consent states, into structured system logic. While technically feasible, these efforts consistently encounter a semantic problem: the protocol terms being encoded do not have a single, invariant meaning. Instead, their interpretation is context-dependent and often only becomes clear when the protocol is implemented across multiple systems such as CTMS, EDC, TMF, and finance. Automation struggles not because systems cannot execute logic, but because they cannot reliably infer what a term is supposed to mean.

Blockchain to Clinical Trial Automation – What Are the Obstacles?

Why promising concepts have not translated into practical implementation? Lessons Learned.

The idea of using blockchain to automate clinical trials emerged from a compelling analogy: if financial contracts can be expressed as executable smart contracts, why not clinical protocols? 

Project Management and Modular Outsourcing

Platforms, GenAI, and modular services. How can this impact Project Management? 

Work organization is evolving across many knowledge-intensive industries. Digital platforms, GenAI-assisted production, and global access to qualified specialists are changing how services are offered, priced, and evaluated. This development is visible even in domains traditionally characterized by strong regulation and institutional structures, like clinical research. Rather than asking whether regulated projects are “moving” to open platforms, a more precise question is:

Swissmedic Submissions and Project Timelines: Why Approval Speed Determines Your Study Start

Clinical trial timelines in Switzerland are tightly linked to the efficiency of submissions to Swissmedic.

Delays at this stage do not remain confined to regulatory milestones. They cascade into site activation, contracts, budgets, and overall project duration.

From a project-management perspective, Swissmedic approval is frequently on the critical path. Even minor, avoidable issues (missing annexes, outdated guidance, inconsistent documents) can postpone study start by weeks or months.

Longevity as a Project

What changes if we consider life as a project?

Projects fail rarely because of one catastrophic event. They fail because small deviations accumulate, risks go unnoticed, and performance is not tracked against expectations. Aging may follow a similar pattern.

Instead of asking “How do we defeat aging?”, we can ask a different question:

What if we consider life as a long-running project, and manage it using basic project control logic?

This reframing does not promise immortality. It proposes something more modest and potentially more useful: governance of healthspan over time.

Project management analogy: Planned, Actual, and Longevity Value

Innovative Mobile Platforms for Clinical Research and Evidence Generation

Advances in mobile technology have opened new pathways for clinical research that go beyond traditional site-centric models. Mobile apps now play a growing role in study visibility, participant engagement, and data collection, both within regulated clinical trials and in healthy-population research.

Rather than replacing clinical trial systems, these platforms operate at a different layer:
they connect people to research, standardise how participation occurs, and enable more continuous, real-world data capture. Over time, this may support more structured datasets, easier study access, and more reliable evidence for analysis and decision-making.

Below are two groups of mobile platforms illustrating this shift.

Mobile Platforms Supporting Clinical Trial Participation

(Patient-facing, trial-specific apps)

Science 37 — Studies App

Focus: Decentralized and hybrid clinical trials

Science 37’s Studies App allows participants to discover, consent to, and take part in clinical trials remotely. The platform reduces dependence on physical sites and lowers participation barriers, particularly for patients who would otherwise not have access to research centers.

• Website: https://www.science37.com

• Google Play: https://play.google.com/store/apps/details?id=com.science37.mobile

"Fit for Purpose" in Clinical Research

One trial, one purpose or many stakeholder perspectives?

The expression “fit for purpose” appears 14 times in **ICH GCP ICH E6(R3). This repetition is not accidental. It signals a deliberate regulatory shift away from rigid, one-size-fits-all compliance toward a more contextual, risk-based understanding of quality, proportionality, and oversight in clinical research.

At the same time, the phrase itself is deceptively simple. According to the Cambridge Dictionary, fit for purpose means:

“Suitable and good enough to do what it is intended to do.”

Fit for Purpose in ICH GCP (R3)

Within ICH GCP E6(R3), fit for purpose is used to describe a wide range of elements, including trial processes, quality management systems, oversight mechanisms, data handling approaches, and supporting technologies. Across all these contexts, the underlying principle is consistent: systems and processes should be appropriate for their intended use, proportionate to risk, and focused on what truly matters for participant safety and reliable decision-making.

"Quality by Design" in Clinical Trials

What is Quality by Design according to ICH GCP E6(R3)? 

E6(R3) Good Clinical Practice (GCP) places Quality by Design as a a key and recurring principle across the guideline. The concept is introduced in the context of clinical study design, risk identification, and planning, and is reinforced at multiple points throughout the document as follows:

FDA Warning Letters to Investigators: Tutorial Examples

FDA warning letters are most often associated with manufacturing or product-related issues, but they can also be issued directly to clinical investigators when significant regulatory concerns are identified during inspections. 

These letters are typically issued months after the underlying events, following:

• an on-site inspection,

• documented observations,

• and review of written responses provided by the investigator or site.

As a result, a warning letter may appear long after the clinical activity in question has already concluded.

Here are 2 examples from December 2025:

• Example 1  - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purushothaman-damodara-kumaran-md-721325-12222025
• Example 2 - https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/devalingam-mahalingam-md-phd-721145-12112025

What such letters generally indicate

The Ten "Commandments" of AI in Drug Development

Guiding Principles of Good AI Practice in Drug Development, January 2026 (https://www.fda.gov/media/189581/download)

In January 2026, the U.S. Food and Drug Administration, together with international regulatory partners, published ten principles for Good AI Practice in Drug Development:

1. Human-centric by design

2. Risk-based approach

3. Adherence to standards

4. Clear context of use

5. Multidisciplinary expertise

6. Data governance and documentation

7. Model design and development practices

8. Risk-based performance assessment

9. Life cycle management

10. Clear, essential information

These principles are presented as a foundation for further work rather than a finalized implementation framework. They describe what regulators consider important when AI is used to generate evidence across the drug product life cycle, without defining how these expectations should be met in specific technical or organizational settings.

At this stage, the document is intentionally high-level. Practical interpretation and operationalization will likely evolve through continued dialogue between regulators, industry, standards bodies, and technology developers.

https://www.raps.org/news-and-articles/news-articles/2026/1/ema-fda-issue-joint-ai-guiding-principles-for-drug

Familiar Concepts in a New Context

Many of the principles may sound familiar to professionals working with established clinical trial systems such as EDC, CTMS, or eTMF platforms. Concepts like risk-based approaches, lifecycle management, data governance, documentation, and adherence to standards are already part of everyday regulatory practice.

What appears different is not the concepts themselves, but the context in which they are now being emphasized. When AI is introduced, familiar expectations are applied to technologies that may behave differently from traditional, rule-based systems. This naturally raises questions about interpretation rather than compliance.

An Open Question Worth Considering

One possible way to read the guidance is to view it as an invitation to reflect:

• Which of these principles are already well understood and operationalized in existing clinical systems?

• Where might AI introduce additional considerations that are less explicit in traditional software development?

• How might established practices evolve as systems move from deterministic behavior toward more adaptive or probabilistic approaches?

These are not questions with immediate or universal answers. They depend heavily on context, use case, system design, and regulatory interaction.

Early Guidance, Not Final Instruction

Importantly, the FDA document does not claim to resolve these questions. Instead, it sets a shared reference point for future discussion and alignment. The absence of technical detail should not be read as a gap, but as recognition that good practice in this area is still emerging and will require time, experimentation, and collaboration to mature.

For now, the principles serve as a common language, useful for orientation, internal discussion, and education.

Closing Note

As AI continues to enter regulated environments, documents like this are likely to be revisited, refined, and expanded. Understanding them as living guidance, rather than fixed rules, may be the most appropriate way to approach them at this stage.

For readers involved in clinical systems, software development, or regulatory oversight, the principles offer a structured way to think about AI, without yet demanding definitive answers.

Disclaimer: This post reflects an educational interpretation of publicly available regulatory guidance and does not constitute regulatory or legal advice.

What a 50% Increase in FDA CDER Warning Letters Tells Us About Quality, Oversight, and System Pressure

According to remarks reported by the Regulatory Affairs Professionals Society, the FDA Center for Drug Evaluation and Research (CDER) issued 50% more warning letters in fiscal year 2025 than in the previous year. This is a notable increase and suggests a change in enforcement activity that warrants closer examination. Whether this reflects a shift in regulatory posture, changes in industry behavior, or increased scrutiny of emerging areas remains an open question.

Rather than treating this figure purely as a headline about enforcement intensity, it is useful to consider what such an increase may indicate about where regulatory attention is currently focused and how oversight adapts as technologies, business models, and supply chains evolve.

Enforcement volume as a signal, not just an outcome

Warning letters are often viewed as the final step in regulatory enforcement. From a systems perspective, they can also be understood as lagging indicators. By the time a warning letter is issued, inspections have occurred, observations have been documented, and responses have been reviewed. Escalation typically reflects a judgment that identified issues were not adequately addressed.

A sharp increase in warning letters therefore raises a broader question:

are regulators encountering more instances of noncompliance, or are they applying closer scrutiny to areas where compliance expectations are still being interpreted and tested?

Innovative Software Solutions in Clinical Research

Clinical research software is often associated with large, enterprise platforms. Alongside these established systems, however, a growing group of specialized and innovation-focused solutions addresses specific pain points such as protocol planning, budgeting, recruitment, operational oversight, and documentation. These tools are frequently adopted as complements to core systems rather than replacements, particularly in regulated environments.

This overview highlights selected software providers that are commonly referenced in discussions about digital transformation in clinical research, with a focus on planning, feasibility, budgeting, and operational coordination.

Protocol Design, Planning, Budgeting and Feasibility

• Espero Health (Sweden) develops software focused on protocol-driven budgeting and feasibility assessment in clinical research. The platform emphasizes deriving cost and effort estimates directly from structured protocol activities and Schedule of Events assumptions, supporting transparency between clinical planning and financial oversight. Website: https://espero-health.com/

• Trials.ai was developed as a decision-support platform for data-driven clinical trial planning. Public information indicates a focus on analyzing historical trial data, literature, and protocol elements to support study design decisions. The company was later acquired and integrated into a larger life-sciences analytics organization, suggesting its capabilities are now embedded in enterprise-level offerings. Website: https://www.trials.ai/

• Risklick is a Switzerland-based company offering software to support structured clinical protocol development, particularly in regulated environments such as medical devices and clinical trials. Its solutions emphasize consistency, reuse of prior knowledge, and alignment with regulatory expectations during protocol authoring. Website: https://www.risklick.ch/, https://www.linkedin.com/company/risklick

• Condor Software provides solutions for clinical trial financial management, including budgeting, forecasting, and site payment processes. The platform focuses on improving transparency and alignment between clinical operations and financial oversight, an area often associated with manual reconciliation and fragmented workflows. Website: https://www.condorsoftware.com/, https://www.linkedin.com/company/condor-software-inc

• Clinical Maestro® by Strategikon is a clinical trial planning and intelligence platform designed to support feasibility assessment, operational forecasting, and data-driven decision-making during study design and portfolio planning. The software focuses on improving transparency and predictability prior to and alongside trial execution rather than replacing core operational systems. Website: https://strategikon.com/, https://www.linkedin.com/company/clinical-maestro/
  

  ProofPilot provides a digital protocol and workflow automation platform intended to reduce manual effort during trial setup and execution. Its emphasis is on standardization, traceability, and structured workflows rather than replacing existing operational systems. Website: https://www.proofpilot.com/, https://www.linkedin.com/company/proofpilot/

Recruitment, Engagement, and Matching

• Pathkey.AI was previously known as Opyl and has since repositioned its focus toward simulation-based clinical trial design and biostatistical validation.
  Website: https://opyl.netlify.app/, https://www.linkedin.com/company/pathkeyai/

• TrialX offers tools that help patients and clinicians identify suitable clinical trials based on eligibility criteria, with the goal of improving accessibility and reducing recruitment delays. Website: https://www.trialx.com/, https://www.linkedin.com/company/trialx/ 

• Hekma is a patient-centric, medical data science company located in San Francisco Bay Area that is dedicated to improving clinical trials and accelerating drug approval. Website: https://www.hekma.ai/, https://www.linkedin.com/company/hekma/

Documentation and Structured Knowledge

• Yseop provides software supporting structured medical and regulatory documentation, including clinical study reports and narratives. The platform emphasizes controlled language, consistency, and traceability—key requirements in regulated clinical environments.
  Website: https://yseop.com/, https://www.linkedin.com/company/yseop/
  

• Merative (formerly Truven Health Analytics, later part of IBM Watson Health) provides large-scale healthcare and real-world evidence analytics used across life sciences, payer, and outcomes research. Website: https://www.merative.com/truven, https://www.linkedin.com/showcase/truven-by-merative/about/

Quality and Regulatory Considerations

All software used in clinical research must operate within established quality and regulatory frameworks, particularly for studies conducted under FDA or EMA oversight. Regardless of innovation level, such tools are expected to support data integrity, audit trails, access control, and validation appropriate to their intended use. As a result, many innovative solutions are positioned as decision-support or planning layers, complementing validated core systems rather than replacing them.

Toward Future Software Evaluation

As digital transformation in clinical research continues, independent and experience-based software evaluation becomes increasingly relevant. Beyond feature descriptions, meaningful assessment requires understanding how tools integrate into operational workflows, quality systems, and regulatory constraints.

This blog aims to document and observe these developments over time. Future posts may explore individual solutions in more depth, focusing on use cases, limitations, and integration considerations, rather than promotional claims.

How to Access and Read FDA Warning Letters (A Practical Guide for a Tutorial)

FDA warning letters are publicly available and can be read in full. They are one of the most transparent regulatory resources for understanding how quality and compliance issues are identified and described by regulators.

Official FDA Warning Letter Repository

All FDA warning letters are published on the official FDA website:

👉 FDA Warning Letters Database
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

This repository is maintained by the U.S. Food and Drug Administration and is updated regularly.

How the repository is structured

On the FDA warning letters page, you can:

• Browse warning letters by year

• Filter by FDA center (e.g. drugs, biologics, devices)

• Search by company name

• Search by subject or keyword

Each entry links to a PDF or HTML letter issued directly by the FDA.

What to look for when reading a warning letter

For educational purposes, it is useful to read warning letters systematically rather than casually. Key sections to focus on include:

1. Inspection background
   Describes when and why the FDA inspection or review took place.

2. Observed violations
   Lists specific regulatory deficiencies, often referencing CFR sections.

3. Regulatory interpretation
   Explains why the FDA considers the findings significant.

4. Expected corrective actions
   Indicates what the FDA expects the organization to address.

5. Potential consequences
   Outlines possible enforcement actions if issues are not resolved.

Reading these sections helps build familiarity with how regulators reason, not just what rules exist.

Why warning letters are useful learning material

Unlike guidance documents, warning letters:

• reflect actual failures, not hypothetical scenarios,

• show how regulations are applied in practice,

• reveal recurring patterns across organizations and time,

• illustrate the link between operational decisions and regulatory outcomes.

For students of clinical research, quality, or project management, they offer insight into system-level weaknesses that are difficult to see in controlled examples.

Using warning letters responsibly

Warning letters should not be read as:

• judgments of intent,

• proof of misconduct beyond what is stated,

• or definitive conclusions about patient harm.

They should be read as regulatory signals: indicators that systems, processes, or controls did not perform as expected.

A suggested exercise (an illustration for learning)

A simple educational approach is to:

1. Select one warning letter from the FDA database.

2. Identify the main category of violation (e.g. GMP, clinical research, labeling).

3. Ask what project, process, or system failure likely contributed.

4. Consider what preventive controls could have reduced the risk.

This turns regulatory documents into learning artifacts, rather than compliance anecdotes.

Reducing Clinical Trial Complexity

What recent publications and reports are pointing to. Evidence and open questions.

Clinical trials are essential for evaluating the safety and efficacy of new therapies, but the operational and financial burden of modern trials has grown significantly over recent decades. Trials are becoming more complex, expensive, and difficult to execute. These often require elaborated protocol designs, extensive regulatory documentation, and multi-site coordination. All of which contribute to longer timelines and higher costs. Recent analyst commentary on the clinical trials industry highlights complexity as a core challenge limiting feasibility. https://www.clinicaltrialsarena.com/features/clinical-trials-challenges-expect-2025

At the same time, funding disruptions have had measurable impacts on clinical research feasibility. A study published in JAMA Internal Medicine reported that NIH grant terminations disrupted approximately 3.5 % of active federally funded clinical trials, affecting over 74,000 enrolled participants and resulting in significant lost funding. These kinds of funding cutbacks do not reflect scientific failure but rather resource constraints that force studies to halt or terminate early. https://www.ajmc.com/view/nih-grant-terminations-disrupt-1-in-30-clinical-trials-impacting-over-74-000-participants

Operational burden and complexity not only challenge sponsors financially but also increase the risk of failure for individual trials and patient safety. A broad literature review of why clinical trials fail identifies high operational and financial burden as one of the factors associated with trial discontinuation, alongside recruitment challenges and design issues. This evidence reinforces the idea that cost and complexity are practical constraints in trial implementation. https://pmc.ncbi.nlm.nih.gov/articles/PMC6092479/

In response to these challenges, researchers and industry groups have begun to develop tools and frameworks to measure and mitigate complexity. A 2025 methodological study introduced a protocol complexity tool that quantifies different aspects of a trial’s design (operational execution, regulatory burden, patient/site burden, etc.) and correlates complexity scores with key trial indicators such as site activation and recruitment timelines. The aim is to provide evidence-based simplification without compromising scientific or ethical standards. https://www.researchgate.net/publication/395032442_Development_of_a_protocol_complexity_tool_a_framework_designed_to_stimulate_discussion_and_simplify_study_design

Beyond individual tools, advocacy from researchers and consortia highlights broader systemic barriers, such as regulatory fragmentation and administrative burden, which can delay trial start-up and reduce feasibility, especially in multinational research contexts. For example, groups in the EU have called for regulatory alignment and reduced administrative complexity to support clinical research across member states, recognizing that procedural obstacles repeatedly delay studies and increase costs. https://eatris.eu/news/clinical-trial-community-seek-urgent-implementation-of-life-science-strategy-as-european-research-becomes-increasingly-endangered/ 

These strands of evidence do not claim that simplification alone will guarantee more lifesaving drugs, nor that reducing cost automatically improves scientific reliability, but they do support a conditional hypothesis: if a large share of current trial resources is consumed by procedural complexity and cost burden rather than core scientific evaluation, then reducing unnecessary complexity could make some studies more operationally feasible within existing budgets, possibly enabling a broader set of research questions to be pursued. https://zenodo.org/records/15651378 

Open question: Does reducing administrative and operational complexity without weakening scientific standards actually free up resources to support additional trials, and could that in turn accelerate meaningful clinical advances? This remains a continuing area of professional and methodological inquiry rather than a settled fact. Recent publications and tool development efforts suggest it is a practical, evidence-informed question worth exploring.

More on this topic in my earlier posts: 

1. Trial–Project Dualism: An Operational View https://www.project-owner.com/2025/12/trialproject-dualism-operational-view.html
2. Structuring Project Complexity: Reviewing Patents related to Project Management https://www.project-owner.com/2025/05/structuring-project-complexity.html
3. From Digitalization to Digital Transformation in Clinical Research https://www.project-owner.com/2025/07/from-digitalization-to-digital.html

Blogging in the GenAI Age: Why Writing May Still Matter in 2026

Blogging in 2026 looks questionable. Most people no longer read blogs and long posts. Information is searched, skimmed, or delegated to generative AI. Even thoughtful posts may attract little attention, while AI can generate fluent text instantly. Against this background, blogging no longer functions reliably as a communication channel. The relevant question is therefore not how to grow a blog, but whether blogging still serves a meaningful purpose.

One answer is epistemic. Blogging has increasingly become a way of documenting reasoning rather than broadcasting information. Generative AI produces language at scale, but it does not assess novelty, truth, or justification. It optimizes for plausibility, not for being right for the right reasons. When humans write carefully, make assumptions explicit, and acknowledge uncertainty, they leave traces of reasoning that are qualitatively different from synthetic text. Blogging, in this sense, preserves human judgment in public form.

This matters not only for readers, but also for the stability of AI systems. A 2024 Nature paper showed that when generative models are trained recursively on content produced by earlier models, performance degrades, diversity collapses, and errors reinforce over time. This phenomenon is known as model collapse. The study is not about blogs specifically, but it highlights a general mechanism: if new data increasingly lacks grounding in human experience, experimentation, and reasoning, systems become self-referential and brittle. The disappearance of human-authored reasoning from public spaces removes precisely the kind of epistemic input that synthetic systems cannot generate on their own.

At the same time, public writing and blogs can not be treated as reliable input. A 2024 ACM study examining Common Crawl, the largest public web dataset used in AI training, shows that blogs and other websites are included not because they are verified or correct, but because they are publicly available. Publication is treated as implicit permission. As a result, careful reasoning is mixed with speculation, error, and noise. Human-authored text may be necessary to prevent epistemic collapse, but availability alone does not guarantee quality.

Taken together, these findings suggest that the relationship between blogging and AI is unresolved rather than obsolete. Human writing may still be needed to introduce new experiences, reasoning paths, and interpretations into the public record, while the mechanisms for incorporating such material into AI systems remain an open challenge. How this exchange develops will be one of the more interesting questions to watch in 2026.

From the author’s perspective, epistemic motivations do not exclude pragmatic ones. Blogging can also support visibility or credibility, and in some cases writers become trusted one-person commentary channels through consistent, responsible publication. These outcomes are exceptions, but they show that epistemic and practical intentions can coexist.

Blogging in the GenAI age is therefore neither obsolete nor guaranteed to matter. Its value depends on whether human reasoning continues to be expressed publicly, even when attention is scarce and automation is easy.

References: 

• Shumailov, I., Shumaylov, Z., Zhao, Y. et al. AI models collapse when trained on recursively generated data. Nature 631, 755–759 (2024). https://doi.org/10.1038/s41586-024-07566-y 
• Stefan Baack. 2024. A Critical Analysis of the Largest Source for Generative AI Training Data: Common Crawl. In Proceedings of the 2024 ACM Conference on Fairness, Accountability, and Transparency (FAccT '24). Association for Computing Machinery, New York, NY, USA, 2199–2208. https://doi.org/10.1145/3630106.3659033

Trial–Project Dualism

From an operational perspective, clinical research often behaves like a system pulled in two directions at once.

• One direction is scientific: patient safety, protocol adherence, data integrity, ethical oversight.
• The other is operational and financial: timelines, budgets, contracts, resource utilization, delivery commitments.

These two priorities coexist, but they are rarely managed within a single, coherent structure.

One way to visualize this is as two snakes competing around the same clinical core. One snake pulls toward scientific and patient-safety targets. The other pulls toward financial control and project delivery. Both are legitimate. Problems arise when they are managed in isolation.

Traditional clinical systems tend to reinforce this split. CTMS focuses on milestones and tracking. TMF focuses on documentation. Finance systems focus on cost and revenue. None of them fully represent the clinical trial as an integrated operational entity.

This is where the idea of Clinical Project Management Systems (CPMS) becomes relevant. CPMS concept proposes different framing: treating clinical trials explicitly as projects, with scope, deliverables, acceptance criteria, and traceable evidence of completed work.

In this framing, the “trial” and the “project” stop competing. They collapse into what one might informally call a Clinical Troject! A trial in scientific intent, but a project in how it must be executed, verified, and accounted for.

When this integration is missing, the two snakes keep pulling in opposite directions. When it is present, operational decisions become clearer, documentation regains meaning, and financial recognition aligns more naturally with actual work delivered.

From an operational standpoint, this is not a philosophical debate. It is a question of whether clinical research is managed as fragmented activity or as a coherent, accountable project. Here is more:

Clinical Project Management Systems (CPMS): A Project-Centric Reframing of Trial Operations. Zenodo. https://doi.org/10.5281/zenodo.17924337

A Conversation on Information, Correlation, Geometry, and the Birth of Space–Time

November 2025: I asked ChatGPT 5.1 to update me on recent ideas in physics and to help me explore a few questions I had been thinking about. What began as a quick check turned into two days of back-and-forth conversations: part physics, part common sense, part speculation, and occasionally humor.

Out of that discussion came a set of texts we both found interesting enough to keep (ChatGPT persuaded me as usual). This is just a record of an unusual and surprisingly coherent conversation that I don’t want to lose. I’m publishing them here so I can return to them later and revisit the topic, especially the idea that Information, Correlation, and Geometry might be the deeper ingredients from which space and time emerge.

Part 1: A Conversation on Information, Correlation, Geometry, and the Birth of Space–Time

From Digitalization to Digital Transformation in Clinical Research

Digital transformation in clinical research is reshaping how work delivery and financial integrity are monitored. A new concept paper proposes linking Trial Master File (TMF) completeness with project planning and revenue recognition to improve data quality, audit readiness, and financial transparency. By aligning TMF documentation with work breakdown structures and Gantt-based planning, the approach creates an integrated operational-financial model grounded in PMBOK, ICH GCP E6(R3), and accounting standards such as IFRS 15.

Read more: https://zenodo.org/records/16418598

Another recent preprint explores a conceptual AI-H budgeting framework to support structured financial planning in clinical trials. Leveraging ICH M11’s Schedule of Activities and generative AI, the framework supports cost estimation, scenario modeling, and feasibility validation using public protocols. It is designed to improve budget alignment with operational scope and regulatory expectations.

Read more: https://zenodo.org/records/15651378

Inflammation (&Aging): Damage or Defence?

Inflammation is often described as something to "fight" or "reduce," especially in the context of food supplements and wellness products. But inflammation itself is a natural defense mechanism, essential for repairing damage and fighting infection.

So is reducing inflammation always beneficial? 

Not necessarily. Blanket suppression of inflammation can be counterproductive, especially if the underlying causes remain unaddressed. Instead, it's more meaningful to first ask:

What is driving chronic, low-grade inflammation in the body? Can it be addressed at the root?

To explore this, I asked ChatGPT to summarize the most frequent and important biological causes of chronic inflammation, how typical inflammation-reduction strategies affect them, and which tests might help individuals investigate these issues through self-research. 

The table below is for illustrative purposes only and not a medical recommendation, as it may contain simplifications or irregularities.

#	Frequent root cause (mechanism)	What generic inflammation-reduction does (symptom focus)	How to tackle the root damage	Most useful test(s)*
1	Mitochondrial dysfunction → mtDNA leakage (often worsened by NAD⁺ decline, oxidative stress)	Temporarily lowers cytokines but leaves damaged mitochondria and DNA debris in place	- Boost NAD⁺ (nicotinamide riboside/mononucleotide) - Support mitophagy (exercise, time-restricted eating, urolithin A)	Plasma/serum cell-free mtDNA, 8-OHdG urine, NAD⁺ metabolomics panel
2	Cellular senescence + SASP (senescent cells secrete pro-inflammatory factors)	Masks SASP cytokines; senescent cells keep pumping them out	- Senolytics (quercetin + dasatinib, fisetin) - Immune-mediated clearance (exercise, fasting)	p16INK4a mRNA (blood), SA-β-gal staining (biopsies), circulating SASP panel
3	Gut-barrier dysfunction / “leaky gut” (LPS, dysbiosis)	Reduces systemic spill-over signals but gut wall still leaking	- Diverse/high-fiber diet, pre-/probiotics - Address SIBO, food intolerances, stress	Zonulin, LPS-binding protein, stool microbiome sequencing
4	Adipose tissue inflammation / insulin resistance (obesity, high fructose, sedentary life)	Lowers IL-6 & TNF-α transiently, but adipocytes remain hypertrophic	- Sustainable fat loss, resistance training - Glycemic control (CGM, low-GI diet)	Waist-to-height ratio, fasting insulin, HbA1c, hs-CRP
5	Latent viral burden (CMV, EBV, herpes family)	Blunts flare-ups yet virus stays latent & immuno-ageing continues	- Antiviral therapy if indicated - Vaccines (where available) - Immune fitness: sleep, micronutrients	CMV/EBV IgG titres, T-cell CD8/CD57 profiling
6	Environmental & occupational toxins (PM2.5, heavy metals, organics)	Reduces oxidative cytokines, but exposure keeps triggering damage	- Air filtration, PPE, remove sources - Support detox (adequate protein, antioxidants)	Blood/urine heavy-metal panel, indoor PM monitoring, serum CRP trend
7	Sleep debt / circadian disruption (shift work, blue light)	Calms some IL-6 & CRP spikes but fatigue and hormonal dys-sync persist	- Prioritise 7–9 h consistent sleep, morning light, melatonin hygiene	Wearable sleep staging + HRV, salivary cortisol, hs-CRP
8	Early autoimmune activation / loss of tolerance	Blunts flare damage but may hide mounting auto-antibodies	- Identify triggers (infections, foods) - Immune-modulating diet, stress reduction - Specialist follow-up if titers rise	ANA panel, specific auto-antibody assays, ESR/CRP

⚠️ Potential Adverse Effects of Anti-Inflammatory Supplements

However, natural doesn’t always mean risk-free. Even anti-inflammatory supplements can cause side effects—especially at high doses or when combined with medications. Here are some examples summarized by ChatGPT and a review per citation (7) below for illustrative purpose.

Supplement Potential Adverse Effects

Curcumin (Turmeric) Nausea, reflux, diarrhea, liver enzyme elevation (rare), increased bleeding risk, possible immune suppression

Quercetin Headache, kidney strain at high doses, drug interactions (e.g., cyclosporine), may affect iron absorption

Resveratrol Estrogenic activity concerns, interference with medications, GI discomfort

Boswellia (Frankincense) Skin rash, GI issues, may interact with NSAIDs or anticoagulants

Omega-3 (Fish oil) Thinning of blood (higher bleeding risk), fishy aftertaste, GI upset, potential immune suppression at high doses

Green Tea Extract (EGCG) Liver toxicity at high doses, insomnia, drug interactions (e.g., warfarin)

Ginger Heartburn, gas, bleeding risk, may lower blood sugar excessively

Willow Bark Similar to aspirin – risk of stomach irritation, allergic reactions, bleeding, avoid with NSAIDs or anticoagulants

---

🔖 References 

1. Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. The Journals of Gerontology: Series A, 69(Suppl_1), S4–S9. https://doi.org/10.1093/gerona/glu057

2. Furman, D. et al. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0

3. Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024). The senescence-associated secretory phenotype and its physiological and pathological implications. Nature Reviews Molecular Cell Biology, 25, 958–978. https://doi.org/10.1038/s41580-024-00727-x 

4. Weyh, C., Krüger, K., & Strasser, B. (2020). Physical Activity and Diet Shape the Immune System during Aging. Nutrients, 12(3), 622. https://doi.org/10.3390/nu12030622 

5. Venter, C., Greenhawt, M., Meyer, R. W., et al. (2022). Role of Dietary Fiber in Promoting Immune Health—An EAACI Position Paper. Allergy, 77(11), 3185–3198. https://doi.org/10.1111/all.15430 

6. Chini, C.C.S., Reid, A.G., Kumar, S., Mitchell, S.J., & Chini, E.N. (2025, June). Chronic Cellular NAD⁺ Depletion Activates a Viral Infection‑Like Interferon Response Through Mitochondrial DNA Leakage. Aging Cell, 24(6), e70135. https://doi.org/10.1111/acel.70135

7. Liu, S.; Liu, J.; He, L.; Liu, L.; Cheng, B.; Zhou, F. A Comprehensive Review on the Benefits and Problems of Curcumin with Respect to Human Health. Molecules 2022, 27, 4400. https://doi.org/10.3390/molecules27144400

--

⚠️ Disclaimer

This is a ChatGPT-assisted post and is intended for educational and self-research purposes only. It does not constitute medical advice or diagnosis. Always consult a qualified healthcare provider before making any changes to your health practices or interpreting test results.